
    
      This is a phase I/II, open-label, single-arm study of ATG 016 Monotherapy to investigate the
      pharmacokinetics, safety and efficacy in IPSS-R Intermediate Risk and above Myelodysplastic
      Syndrome (MDS) Patients after Failure of Hypomethylating Agent (HMA)-based Therapy.
      Approximately 59 to 65 subjects will be enrolled totally in this study. In phase I,
      approximately 15 to 21 subjects will be enrolled to evaluate the safety and tolerability for
      treatment with ATG-016 . And In phase II, approximately 44 subjects will be enrolled to
      evaluate the efficacy for treatment with ATG 016.
    
  